The Impact of Positron Emission Tomography on Clinical Decision Making in a University-Based Multidisciplinary Lung Cancer Practice

Sachs, Sharona; Bilfinger, Thomas V.

doi:10.1378/chest.128.2.698

Cited by 37 publications

(19 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…15 We noted similar staging differences in our study. For primary lung nodules, the most important issue is to distinguish malignant from benign lesions.…”

Section: Discussionsupporting

confidence: 88%

Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer

Nakamura

Taguchi

Kitamura

et al. 2008

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

show abstract

“…15 We noted similar staging differences in our study. For primary lung nodules, the most important issue is to distinguish malignant from benign lesions.…”

Section: Discussionsupporting

confidence: 88%

Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer

Nakamura

Taguchi

Kitamura

et al. 2008

Gen Thorac Cardiovasc Surg

View full text Add to dashboard Cite

show abstract

“…18 F-FDG PET has a high accuracy for staging non-small cell lung cancer, gastrointestinal tract cancers (i.e., esophageal and colorectal cancer), malignant lymphoma, melanoma, thyroid cancer, and head and neck cancer. Depending on the tumor subtype, changes in therapeutic management of between 15% and 40% based on PETor PET/ CT findings have been described (2,4,5,15,16). Some tumors, such as prostate cancer or neuroendocrine cancer, do not exhibit increased glucose use, leading to false-negative findings on 18 F-FDG PET.…”

Section: Tumor Staging and Prognostic Stratificationmentioning

confidence: 99%

Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches

Buck¹,

Herrmann²,

Stargardt³

et al. 2010

Journal of Nuclear Medicine Technology

107

View full text Add to dashboard Cite

PET and PET/CT have changed the diagnostic algorithm in oncology. Health care systems worldwide have recently approved reimbursement for PET and PET/CT for staging of non-small cell lung cancer and differential diagnosis of solitary pulmonary nodules because PET and PET/CT have been found to be cost-effective for those uses. Additional indications that are covered by health care systems in the United States and several European countries include staging of gastrointestinal tract cancers, breast cancer, malignant lymphoma, melanoma, and head and neck cancers. Regarding these indications, diagnostic effectiveness and superiority over conventional imaging modalities have been shown, whereas cost-effectiveness has been demonstrated only in part. This article reports on the current knowledge of economic evaluations of PET and PET/CT in oncologic applications. Because more economic evaluations are needed for several clinical indications, we also report on the methodologies for conducting economic evaluations of diagnostic tests and suggest an approach toward the implementation of these tests in future clinical studies.

show abstract

“…FDG-PET has high accuracy for staging non-small-cell lung cancer, gastrointestinal tract cancers including colorectal and esophageal cancer, thyroid cancer, head and neck cancer, melanoma and lymphoma (Buck et al, 2010). Changes in therapeutic management in 15%e40% of patients due to findings on PET/CT have been reported Seam et al, 2007;von Schulthess et al, 2006;Pieterman et al, 2000;Sachs and Bilfinger, 2005). Some tumors, such as neuroendocrine cancers, do not exhibit increased glucose uptake and are therefore not as well suited for staging by FDG-PET/CT (Buck et al, 2010).…”

Section: Fdg-pet/ctmentioning

confidence: 99%

Molecular imaging for personalized cancer care

2012

View full text Add to dashboard Cite

Molecular imaging is rapidly gaining recognition as a tool with the capacity to improve every facet of cancer care. Molecular imaging in oncology can be defined as in vivo characterization and measurement of the key biomolecules and molecularly based events that are fundamental to the malignant state. This article outlines the basic principles of molecular imaging as applied in oncology with both established and emerging techniques. It provides examples of the advantages that current molecular imaging techniques offer for improving clinical cancer care as well as drug development. It also discusses the importance of molecular imaging for the emerging field of theranostics and offers a vision of how molecular imaging may one day be integrated with other diagnostic techniques to dramatically increase the efficiency and effectiveness of cancer care.

show abstract

The Impact of Positron Emission Tomography on Clinical Decision Making in a University-Based Multidisciplinary Lung Cancer Practice

Cited by 37 publications

References 21 publications

Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer

Fluorodeoxyglucose positron emission tomography integrated with computed tomography to determine resectability of primary lung cancer

Economic Evaluation of PET and PET/CT in Oncology: Evidence and Methodologic Approaches

Molecular imaging for personalized cancer care

Contact Info

Product

Resources

About